CoChat
Sign Up
Cited by 25Lipoproteins and Cardiovascular HealthLipid metabolism and disordersCholesterol and Lipid Metabolism

Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Lipoprotein(a)

Open access
Rivera, Frederick Berro, Cha, Sung Whoy, Linnaeus Louisse, Cruz, Carado, Genquen Philip, Magalong, John Vincent, Tang, Vincent Anthony, Enriquez, Mary Grace, Gulati, Martha +3 more·2025·JACC: Advances
DOI 10.1016/j.jacadv.2024.101549PMC PMC11773245
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: Lipoprotein(a) [Lp(a)] has been independently associated with increased cardiovascular risk. Objectives: The authors examined the effect of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is) on plasma Lp(a) levels across multiple trials. Methods: Studies were retrieved comparing the effect of PCSK9i vs placebo on Lp(a) levels. The primary outcome was percent change in Lp(a) levels. Factors associated with the treatment effect were determined by meta-regression analysis. Subgroup analyses were done to explore potential treatment effect differences. Results: interaction < 0.01. Conclusions: PCSK9is reduce Lp(a) levels by an average of 27%. Mean percent change in low-density lipoprotein cholesterol and apolipoprotein B were associated with treatment effect.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jacadv.2024.101549

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Obicetrapib was associated with a 37% reduction in Lp(a) levels, which is higher than the average reduction of 27% observed with PCSK9 inhibitors.

    “Obicetrapib was associated with a 37 % reduction in Lp(a) levels, which is higher than the average reduction of 27 % observed with PCSK9 inhibitors [29].”

    From Efficacy and safety of obicetrapib in patients with dyslipidemia: An updated meta-analysis of randomized controlled trials (2025) · cites this paper as [29]

    The Results section (page unavailable) reports an average 27% reduction in Lp(a) with PCSK9 inhibitors compared with placebo or ezetimibe. The paper does not report a 37% reduction with obicetrapib, so it supports only the PCSK9-inhibitor portion of the comparison. (LLM, conf=0.89)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 59

  1. [1]Laschkolnig A. Kollerits B. Lamina C. Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts Cardiovasc Res 103 1 2014 28 36 24760552 PMC4065111
  2. [2]Gurdasani D. Sjouke B. Tsimikas S. Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC Norfolk prospective population study Arterioscler Thromb Vasc Biol 32 12 2012 3058 3065 23065826 PMC4210842
  3. [3]Schmidt K, Noureen A, Kronenberg FA-O, et al. Structure, function, and genetics of lipoprotein (a) A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies Lipoprotein(a): the revenant Lipoprotein(a) Gets Worse Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies Lipoprotein(a). Elsevier. 1539-7262.
  4. [4]Kostner K.M. Kostner G.M. Lipoprotein(a): still an enigma? Curr Opin Lipidol 13 4 2002 391 396 12151854
  5. [5]Kronenberg F. Mora S. Stroes E.S.G. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement Eur Heart J 43 39 2022 3925 3946 36036785 PMC9639807
  6. [6]Reyes-Soffer G. Ginsberg H.N. Berglund L. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American heart association Arterioscler Thromb Vasc Biol 42 1 2022 e48 e60 34647487 PMC9989949
  7. [7]O'Donoghue M.L. Fazio S. Giugliano R.P. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk Circulation 139 12 2019 1483 1492 30586750
  8. [8]Verwer M.C. Waissi F. Mekke J.M. High lipoprotein(a) is associated with major adverse limb events after femoral artery endarterectomy Atherosclerosis 349 2022 196 203 34857353
  9. [9]Reyes-Soffer G. Pavlyha M. Ngai C. Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans Circulation 135 4 2017 352 362 27986651 PMC5262523
  10. [10]Bittner V.A. Szarek M. Aylward P.E. Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome J Am Coll Cardiol 75 2 2020 133 144 10.1016/j.jacc.2019.10.057 31948641 · DOI · Paper page
  11. [12]Liberati A. Altman D.G. Tetzlaff J. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ 339 2009 b2700 PMC2714672 19622552
  12. [13]Schwingshackl L. Rüschemeyer G. Meerpohl J.J. [How to interpret the certainty of evidence based on GRADE (Grading of recommendations, assessment, development and evaluation)] Urologe 60 4 2021 444 454 33620513
  13. [14]Sideri S. Papageorgiou S.N. Eliades T. Registration in the international prospective register of systematic reviews (PROSPERO) of systematic review protocols was associated with increased review quality J Clin Epidemiol 100 2018 103 110 29339215
  14. [16]Ako J. Hibi K. Tsujita K. Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndrome — the ODYSSEY J-IVUS trial Circ J 83 10 2019 2025 2033 31434809
  15. [17]Bays H. Gaudet D. Weiss R. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial J Clin Endocrinol Metab 100 8 2015 3140 3148 26030325 PMC4524987
  16. [19]Blom D.J. Harada-Shiba M. Rubba P. Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH trial J Am Coll Cardiol 76 2 2020 131 1819 32646561
  17. [20]Boccara F. Kumar P.N. Caramelli B. Evolocumab in HIV-infected patients with dyslipidemia: primary results of the randomized, double-blind BEIJERINCK study J Am Coll Cardiol 75 20 2020 2570 2584 32234462
  18. [21]Cannon C.P. Cariou B. Blom D. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial Eur Heart J 36 19 2015 1186 1194 25687353 PMC4430683
  19. [22]Chao T.H. Hsiao P.J. Liu M.E. A subanalysis of Taiwanese patients from ODYSSEY South Korea and Taiwan study evaluating the efficacy and safety of alirocumab J Chin Med Assoc 82 4 2019 265 271 30946207
  20. [23]Farnier M. Jones P. Severance R. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial Atherosclerosis 244 2016 138 146 26638010
  21. [24]Ginsberg H.N. Rader D.J. Raal F.J. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg/dl or higher Cardiovasc Drugs Ther 30 5 2016 473 483 27618825 PMC5055560
  22. [25]Han Y. Chen J. Chopra V.K. Odyssey EAST: alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand J Clin Lipidol 14 1 2020 98 108.e8 31882376
  23. [26]Hao Y. Yang Y.L. Wang Y.C. Li J. Effect of the early application of evolocumab on blood lipid profile and cardiovascular prognosis in patients with extremely high-risk acute coronary syndrome Int Heart J 63 4 2022 669 677 35831153
  24. [27]Hirayama A. Honarpour N. Yoshida M. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study Circ J 78 5 2014 1073 1082 24662398
  25. [28]Janik M.J. Urbach D.V. van Nieuwenhuizen E. Alirocumab treatment and neurocognitive function according to the CANTAB scale in patients at increased cardiovascular risk: a prospective, randomized, placebo-controlled study Atherosclerosis 331 2021 20 27 34303265
  26. [29]Kastelein J.J. Ginsberg H.N. Langslet G. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia Eur Heart J 36 43 2015 2996 3003 26330422 PMC4644253
  27. [31]Kiyosue A. Honarpour N. Kurtz C. Xue A. Wasserman S.M. Hirayama A. A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk Am J Cardiol 117 1 2016 40 47 26547291
  28. [32]Koh K.K. Nam C.W. Chao T.H. A randomized trial evaluating the efficacy and safety of alirocumab in South Korea and Taiwan (ODYSSEY KT) J Clin Lipidol 12 1 2018 162 72e6 29153823
  29. [33]Koren M.J. Scott R. Kim J.B. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo controlled, phase 2 study Lancet 380 9858 2012 1995 2006 23141812
  30. [34]Koren M.J. Lundqvist P. Bolognese M. Anti PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab J Am Coll Cardiol 63 23 2014 2531 2540 24691094
  31. [35]Koskinas K.C. Windecker S. Pedrazzini G. Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS) J Am Coll Cardiol 74 20 2019 2452 2462 31479722
  32. [36]Cariou B. Leiter L.A. Müller-Wieland D. Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: rationale and design of the ODYSSEY DM-INSULIN trial Diabetes Metab 43 5 2017 453 459 28347654
  33. [37]Lorenzatti A.J. Eliaschewitz F.G. Chen Y. Rationale and design of a randomized study to assess the efficacy and safety of evolocumab in patients with diabetes and dyslipidemia: the BERSON clinical trial Clin Cardiol 41 9 2018 1117 1122 29962050 PMC6489947
  34. [38]McKenney J.M. Koren M.J. Kereiakes D.J. Hanotin C. Ferrand A.C. Stein E.A. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy J Am Coll Cardiol 59 25 2012 2344 2353 22463922
  35. [40]Nissen S.E. Nicholls S.J. Results of the GLAGOV trial CCJM 84 12 suppl 4 2017 e1 e5 29281604
  36. [41]Nissen S.E. Stroes E. Dent-Acosta R.E. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial JAMA 315 15 2016 1580 1590 27039291
  37. [42]Raal F. Scott R. Somaratne R. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial Circulation 126 20 2012 2408 2417 23129602
  38. [43]Raal F.J. Stein E.A. Dufour R. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial Lancet 385 9965 2015 331 340 25282519
  39. [44]Raal F.J. Honarpour N. Blom D.J. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial Lancet 385 9965 2015 341 350 25282520
  40. [45]Robinson J.G. Nedergaard B.S. Rogers W.J. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial JAMA 311 18 2014 1870 1882 24825642
  41. [46]Robinson J.G. Farnier M. Krempf M. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events N Engl J Med 372 16 2015 1489 1499 25773378
  42. [47]Rosenson R.S. Daviglus M.L. Handelsman Y. Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study Diabetologia 62 6 2019 948 958 30953107 PMC6509076
  43. [48]Roth E.M. McKenney J.M. Hanotin C. Asset G. Stein E.A. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia N Engl J Med 367 20 2012 1891 1900 23113833
  44. [49]Roth E.M. McKenney J.M. ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks Future Cardiol 11 1 2015 27 37 25606700
  45. [50]Roth E.M. Moriarty P.M. Bergeron J. A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I Atherosclerosis 254 2016 254 262 27639753
  46. [53]Stein E.A. Gipe D. Bergeron J. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial Lancet 380 9836 2012 29 36 22633824
  47. [54]Stiekema L.C.A. Stroes E.S.G. Verweij S.L. Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment Eur Heart J 40 33 2019 2775 2781 30561610 PMC6933872
  48. [55]Stroes E. Colquhoun D. Sullivan D. Anti PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab J Am Coll Cardiol 63 23 2014 2541 2548 24694531
  49. [56]Stroes E. Guyton J.R. Lepor N. Efficacy and safety of alirocumab 150 mg every 4 Weeks in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II study J Am Heart Assoc 5 9 2016 e003421 27625344 PMC5079013
  50. [58]Teramoto T. Kobayashi M. Tasaki H. Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins - ODYSSEY Japan randomized controlled trial Circ J 80 9 2016 1980 1987 27452202
  51. [59]Teramoto T. Kiyosue A. Ishigaki Y. Efficacy and safety of alirocumab 150mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON J Cardiol 73 3 2019 218 227 30509509
  52. [60]Watts G.F. Chan D.C. Dent R. Factorial effects of evolocumab and atorvastatin on lipoprotein metabolism Circulation 135 4 2017 338 351 27941065
  53. [61]Zhu L. Fang Y. Gao B. Effect of an increase in Lp(a) following statin therapy on cardiovascular prognosis in secondary prevention population of coronary artery disease [published correction appears in BMC Cardiovasc Disord. 2022 Dec 30;22(1):577 BMC Cardiovasc Disord 22 1 2022 474 10.1186/s12872-022-03027-4 36348286 PMC9644478 · DOI
  54. [62]Watts G.F. Chan D.C. Somaratne R. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics Eur Heart J 39 2018 2577 2585 10.1093/eurheartj/ehy122 29566128 · DOI
  55. [63]Shapiro M.D. Miles J. Tavori H. Fazio S. Diagnosing resistance to a proprotein convertase subtilisin/kexin type 9 inhibitor Ann Intern Med 168 5 2018 376 379 29181527
  56. [64]Rhainds D. Brodeur M.R. Tardif J.C. Lipoprotein (a): when to measure and how to treat? Curr Atherosclerosis Rep 23 9 2021 51 34235598
  57. [65]Farmakis I. Doundoulakis I. Pagiantza A. Lipoprotein(a) reduction with proprotein convertase subtilisin/kexin type 9 inhibitors: a systematic review and meta-analysis J Cardiovasc Pharmacol 77 3 2021 397 407 33298738
  58. [66]Yu Z. Hu L. Sun C. Effect of different types and dosages of proprotein convertase subtilisin/kexin type 9 inhibitors on lipoprotein(a) levels: a network meta-analysis J Cardiovasc Pharmacol 81 6 2023 445 453 36972559
  59. [67]Madsen C.M. Kamstrup P.R. Langsted A. Varbo A. Nordestgaard B.G. Lipoprotein(a)- lowering by 50 mg/dL (105 nmol/L) may Be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study Arterioscler Thromb Vasc Biol 40 1 2020 255 266 31578080

Cited by

Sorted by citations

Authors
Rivera, F. B., Cha, S. W., Linnaeus Louisse, C., Carado, G. P., Magalong, J. V., Tang, V. A., Enriquez, M. G., Gulati, M., Enkhmaa, B., Pagidipati, N., & Shah, N. P.
Affiliations
  • Lincoln Medical Center (US)
  • Cebu Institute of Medicine (PH)
  • Philippine General Hospital (PH)
  • University of the Philippines Manila (PH)
  • Cedars-Sinai Smidt Heart Institute (US)
  • UC Davis Health (US)
  • Duke University (US)
Corresponding author
Rivera, Frederick Berro
ORCID
Venue
JACC: Advances
Publisher
Elsevier BV
Published
2025-02
Volume
4
Issue
2
Pages
101549
ISSN
2772-963X (ISSN-L)
DOI
10.1016/j.jacadv.2024.101549
PMC
PMC11773245
OpenAlex
W4406205119
Cited by
25
References
9
Citations by year
2026: 13 · 2025: 12
FWCI
23.52
Type
journal article
Language
en
Open access
Licence
Locations
  • JACC Advances (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
Keywords
PCSK9 inhibitors, lipoprotein(a), monoclonal antibodies, LDL cholesterol, apolipoprotein B, cardiovascular risk, lipid-lowering therapy, treatment effect heterogeneity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review